美国食品和药物管理局批准人工智能心脏斑块分析; 赛格纳将从10月开始在全国范围内进行. FDA approves AI heart plaque analysis; Cigna to cover it nationwide starting October.

美国食品和药物管理局批准了Heartflow的AI驱动的斑块分析技术,该技术使用273,000名患者的数据来可视化冠状动脉斑块类型,帮助更快,更详细地评估心脏病. The FDA has approved Heartflow’s AI-powered plaque analysis technology, which uses data from 273,000 patients to visualize coronary plaque types, aiding in faster, more detailed assessment of heart disease. 从10月开始,根据联合健康组织的早期覆盖决定, 奇格纳(Cigna)将在全国进行这项测试。 Starting in October, Cigna will cover the test nationwide, following UnitedHealth’s earlier coverage decision. 该工具支持临床决策,全面了解广场的位置和严重性,有可能改进冠状动脉疾病的早期发现和治疗规划。 The tool supports clinical decision-making by providing a comprehensive view of plaque location and severity, potentially improving early detection and treatment planning for coronary artery disease.